Pharmaceuticals, Biotechnology and Life Sciences
Sanofi and Regeneron Pharmaceuticals said Friday a Phase 2 proof-of-concept trial evaluating the investigational IL-33 antibody REGN3500 (SAR440340) met the primary endpoint of improvement in loss of asthma control when comparing REGN3500 monotherapy to placebo.
Leading biopharmaceutical organizations join Project Baseline initiative to engage more patients and clinicians in research and speed evidence generation SAN…
The European Commission (EC) has licensed Dupixent (dupilumab), developed by Regeneron and Sanofi, for older than 12 patients as an add-on maintenance treatment for severe asthma with type 2 inflammation.
Sanofi’s dengue vaccien Dengvaxia was approved in the USA, the company said in a press release Thursday.
Global Markets to 2023 with Abbott Laboratories, Bayer Healthcare, GlaxoSmithKline, Merck & Co, Pfizer and Sanofi at the Forefront
NEW YORK–(BUSINESS WIRE)–Schrödinger today announced receipt of a milestone payment from Sanofi (EURONEXT: SAN, NASDAQ: SNY) to mark the advancement…
OSS, The Netherlands–(BUSINESS WIRE)–Lead Pharma, a pharmaceutical company developing innovative medicines for the treatment of immunological and oncological indications, today…
Denali Therapeutics and Sanofi in partnership have started dosing patients in a clinical Phase 1b study of DNL747 in patients with ALS.
Regeneron Pharmaceuticals and Sanofi restructure immuno-oncology agreement from 2015, where Regeneron retains full rights to all its other investigational immunooncology programsto, while Sanofi is able to independently chase own immuno-oncology programs.
A vaccine made by joint effort of Merck and Sanofi Pasteur, the vaccines unit of Sanofi, Vaxelis – for children younger than 5 – got the US FDA’s approval for six active immunization indications.